Complete360® Enables Deep Biomarker Profiling in Groundbreaking iPSC CAR‑NK Cell Therapy Study Published in Cell
June 25, 2025 | BALTIMORE – We are thrilled to share that a major milestone in cell therapy has just been published in Cell, showcasing the world’s first-in-human clinical study of dual-targeting CAR-NK cells derived from induced pluripotent stem cells (iPSCs). The therapy demonstrated promising efficacy with an excellent safety profile—no signs of cytokine release syndrome (CRS), neurotoxicity, or graft-versus-host disease (GvHD). This represents a paradigm shift toward scalable, off-the-shelf immune cell therapy solutions. — But what powers the safety, monitoring, and mechanistic understanding behind such a novel therapy? The answer lies in Complete360®, our proprietary clinical-grade deep plasma proteomics platform.
Complete Omics Makes Landmark Debut at ASMS 2025
June 5, 2025 | BALTIMORE -Complete Omics Inc. is proud to announce a successful debut at the American Society for Mass Spectrometry (ASMS) 2025 Annual Meeting, held in Baltimore, Maryland.
Milestone! | Complete Omics Inc. Secures California Clinical Laboratory License, Expanding Access to Cutting-Edge Clinical Proteomics Testing
Feb 20, 2025 | BALTIMORE – Complete Omics Inc., a leader in clinical proteomics and multi-omics molecular diagnostics, proudly announces its recent achievement of the California Clinical Laboratory License. This milestone marks a pivotal expansion in the company’s ability to serve patients and healthcare providers across California, the most populous state in the U.S.
Milestone! | Complete Omics Inc. Achieves CLIA, CAP Certification, and Medicare Enrollment
Oct 20, 2024 | BALTIMORE – Complete Omics Inc., a trailblazer in clinical proteomics and multi-omics molecular diagnostics, is proud to announce its recent achievement of CLIA and CAP certifications, along with enrollment in the Medicare system. These accomplishments underscore Complete Omics’ unwavering commitment to providing top-tier diagnostic solutions, grounded in excellence and reliability, and advancing patient care through accessible, state-of-the-art clinical proteomics testing services.
Strategic Partnership with M20 Genomics, Advancing Single-Cell Multi-Omics for Precision Medicine
August 20, 2024 | BALTIMORE – Complete Omics is thrilled to announce an electrifying partnership with M20 Genomics, a trailblazer in single-cell and spatial transcriptomics! Together, these industry leaders are embarking on a groundbreaking collaboration set to redefine the landscape of single-cell multi-omics. By merging their cutting-edge technologies, this dynamic alliance is poised to revolutionize disease research and precision medicine, pushing the boundaries of what’s possible in healthcare innovation.
Exciting News | Valid-NEO® Platform Secures U.S. Patent
May 12, 2024 | BALTIMORE – Complete Omics is thrilled to announce that our Valid-NEO® platform’s “Method and System for Neoantigen Analysis” has been granted a U.S. patent after a rigorous three-year review by the USPTO. This breakthrough makes Valid-NEO® the only patented method in the U.S. capable of directly quantifying neoantigens on cell surfaces. This milestone underscores the platform’s significant technical value, setting it apart in the neoantigen detection field.
